|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PTGFR |
Gene summary for PTGFR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PTGFR | Gene ID | 5737 |
| Gene name | prostaglandin F receptor | |
| Gene Alias | FP | |
| Cytomap | 1p31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P43088 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5737 | PTGFR | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 6.04e-16 | 5.93e-01 | -0.0166 |
| 5737 | PTGFR | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 4.31e-19 | 6.05e-01 | -0.0132 |
| 5737 | PTGFR | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 3.47e-18 | 5.62e-01 | -0.013 |
| 5737 | PTGFR | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.34e-13 | 5.32e-01 | -0.0121 |
| 5737 | PTGFR | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.47e-02 | 4.94e-01 | -0.0961 |
| 5737 | PTGFR | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 2.11e-07 | 7.13e-01 | -0.0876 |
| 5737 | PTGFR | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.42e-04 | 6.08e-01 | -0.0822 |
| 5737 | PTGFR | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 8.46e-06 | 5.78e-01 | -0.0809 |
| 5737 | PTGFR | ATC09 | Human | Thyroid | ATC | 6.18e-03 | 1.61e-01 | 0.2871 |
| 5737 | PTGFR | ATC12 | Human | Thyroid | ATC | 3.07e-41 | 8.83e-01 | 0.34 |
| 5737 | PTGFR | ATC1 | Human | Thyroid | ATC | 1.55e-03 | 1.88e-01 | 0.2878 |
| 5737 | PTGFR | ATC2 | Human | Thyroid | ATC | 1.60e-07 | 6.90e-01 | 0.34 |
| 5737 | PTGFR | ATC4 | Human | Thyroid | ATC | 1.97e-49 | 1.08e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00310996 | Cervix | CC | regeneration | 46/2311 | 198/18723 | 1.43e-05 | 2.84e-04 | 46 |
| GO:00426924 | Cervix | CC | muscle cell differentiation | 69/2311 | 384/18723 | 8.12e-04 | 7.09e-03 | 69 |
| GO:0042246 | Cervix | CC | tissue regeneration | 19/2311 | 72/18723 | 9.11e-04 | 7.81e-03 | 19 |
| GO:00434032 | Cervix | CC | skeletal muscle tissue regeneration | 12/2311 | 37/18723 | 1.15e-03 | 9.39e-03 | 12 |
| GO:0000768 | Cervix | CC | syncytium formation by plasma membrane fusion | 15/2311 | 55/18723 | 2.14e-03 | 1.54e-02 | 15 |
| GO:0140253 | Cervix | CC | cell-cell fusion | 15/2311 | 55/18723 | 2.14e-03 | 1.54e-02 | 15 |
| GO:00069491 | Cervix | CC | syncytium formation | 15/2311 | 57/18723 | 3.13e-03 | 2.05e-02 | 15 |
| GO:00511464 | Cervix | CC | striated muscle cell differentiation | 50/2311 | 283/18723 | 5.53e-03 | 3.19e-02 | 50 |
| GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
| GO:003109911 | Liver | Cirrhotic | regeneration | 71/4634 | 198/18723 | 3.02e-04 | 2.65e-03 | 71 |
| GO:00310992 | Liver | HCC | regeneration | 107/7958 | 198/18723 | 6.67e-04 | 4.12e-03 | 107 |
| GO:19016548 | Lung | IAC | response to ketone | 39/2061 | 194/18723 | 1.40e-04 | 2.60e-03 | 39 |
| GO:00323554 | Lung | IAC | response to estradiol | 27/2061 | 141/18723 | 2.89e-03 | 2.60e-02 | 27 |
| GO:19016553 | Lung | IAC | cellular response to ketone | 20/2061 | 96/18723 | 3.58e-03 | 3.00e-02 | 20 |
| GO:00022377 | Lung | IAC | response to molecule of bacterial origin | 56/2061 | 363/18723 | 5.78e-03 | 4.21e-02 | 56 |
| GO:00324967 | Lung | IAC | response to lipopolysaccharide | 53/2061 | 343/18723 | 6.87e-03 | 4.75e-02 | 53 |
| GO:190165413 | Lung | AIS | response to ketone | 34/1849 | 194/18723 | 6.76e-04 | 1.01e-02 | 34 |
| GO:003235511 | Lung | AIS | response to estradiol | 25/1849 | 141/18723 | 2.78e-03 | 2.77e-02 | 25 |
| GO:0019932 | Lung | AIS | second-messenger-mediated signaling | 46/1849 | 312/18723 | 3.79e-03 | 3.52e-02 | 46 |
| GO:190165511 | Lung | AIS | cellular response to ketone | 18/1849 | 96/18723 | 5.64e-03 | 4.76e-02 | 18 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04072 | Lung | IAC | Phospholipase D signaling pathway | 28/1053 | 148/8465 | 1.46e-02 | 5.00e-02 | 3.32e-02 | 28 |
| hsa040721 | Lung | IAC | Phospholipase D signaling pathway | 28/1053 | 148/8465 | 1.46e-02 | 5.00e-02 | 3.32e-02 | 28 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PTGFR | SNV | Missense_Mutation | c.563N>C | p.Tyr188Ser | p.Y188S | P43088 | protein_coding | deleterious(0.02) | possibly_damaging(0.673) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PTGFR | SNV | Missense_Mutation | novel | c.997N>A | p.Trp333Arg | p.W333R | P43088 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| PTGFR | insertion | Frame_Shift_Ins | novel | c.439_440insCACAACCTGCCAGACGGAAAACCGGCTTTCCGTATTTT | p.Ile147ThrfsTer19 | p.I147Tfs*19 | P43088 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| PTGFR | insertion | Nonsense_Mutation | novel | c.631_632insGCAATCCTGCACAGTTTTGAGAGGGAGATGACTTGAGTGG | p.Leu211CysfsTer7 | p.L211Cfs*7 | P43088 | protein_coding | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| PTGFR | insertion | Frame_Shift_Ins | novel | c.290_291insTTTAAAAAATCTTATTGGGTTTAAATCTAATCTTGGTAGCG | p.Glu97AspfsTer43 | p.E97Dfs*43 | P43088 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| PTGFR | insertion | Nonsense_Mutation | novel | c.202_203insATCCCTCCAGAGGCTGATCCCAATGCATCGGCTTCGC | p.Leu68HisfsTer6 | p.L68Hfs*6 | P43088 | protein_coding | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| PTGFR | insertion | Frame_Shift_Ins | novel | c.188_189insCTCACCACTCTGCTTTTCAT | p.Lys63AsnfsTer19 | p.K63Nfs*19 | P43088 | protein_coding | TCGA-BH-A0H6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PTGFR | insertion | In_Frame_Ins | novel | c.190_191insGTT | p.Ala64delinsGlySer | p.A64delinsGS | P43088 | protein_coding | TCGA-BH-A0H6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PTGFR | SNV | Missense_Mutation | novel | c.290A>G | p.Glu97Gly | p.E97G | P43088 | protein_coding | tolerated(0.29) | benign(0.158) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PTGFR | SNV | Missense_Mutation | c.617N>A | p.Ser206Tyr | p.S206Y | P43088 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-A6-6649-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651094 | SULPROSTONE | |
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | LAROPIPRANT | LAROPIPRANT | ||
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650568 | ||
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135649995 | BIMATOPROST | |
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135650113 | CLOPROSTENOL | |
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 178100403 | ||
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651570 | ||
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135649649 | ||
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 187051754 | TAFLUPROST | |
| 5737 | PTGFR | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | CHEMBL1237105 | CARBOPROST TROMETHAMINE |
| Page: 1 2 3 4 5 6 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |